FIELD: biotechnology.
SUBSTANCE: invention relates to fusion proteins based on human SIRPα, and can be used in medicine for anticancer therapy or in the treatment of autoimmune diseases. A fusion protein for binding to the CD47 protein and a tumor-associated antigen is designed comprising the following: a first binding domain that specifically binds the tumor-associated antigen; and a second binding domain containing a human domain mutant SIRPα, which specifically binds the CD47 protein.
EFFECT: invention makes it possible to obtain a fusion protein capable of specifically binding both the CD47 protein and the tumor-associated antigen; and/or is capable of specifically blocking the interaction between the CD47 protein and SIRPα; and/or capable of effectively inhibiting the growth and/or proliferation of tumors or tumor cells.
20 cl, 16 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BINDING OF FUSED PROTEIN TO CD47 PROTEIN AND ITS USE | 2019 |
|
RU2787521C2 |
| FUSION PROTEIN AND ITS USE | 2020 |
|
RU2811120C2 |
| ANTIBODIES TO PROTEIN CD38, AND THEIR USE | 2019 |
|
RU2776795C2 |
| BISPECIFIC ANTIBODY AGAINST RABIES VIRUS AND ITS APPLICATION | 2019 |
|
RU2764740C1 |
| BISPECIFIC FUSION PROTEIN AND ITS USE | 2021 |
|
RU2801528C2 |
| ANTI-HUMAN RECEPTOR-TYPE PROTEIN TYROSINE PHOSPHATASE σ ANTIBODY | 2012 |
|
RU2715642C2 |
| ANTI-CD79B ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF AND PHARMACEUTICAL USE THEREOF | 2020 |
|
RU2817143C2 |
| TETANUS TOXIN ANTIBODY AND USE THEREOF | 2020 |
|
RU2815280C1 |
| FUSION PROTEIN OF DCTN1 PROTEIN WITH RET PROTEIN | 2018 |
|
RU2813996C2 |
| BISPECIFIC ANTIBODY AGAINST CD3E/BCMA AND ITS USE | 2019 |
|
RU2800164C2 |
